Beijing Centergate Technologies (Holding) Co., Ltd. produces and sells topical reagents, tablets, and injections in China. Its portfolio includes treatments for vascular dementia, opioid blockade, moderate to severe pain, hypertension, angina, arrhythmia, anxiety disorders, hyperuricemia, asthma, bronchitis, type 2 diabetes, and nausea and vomiting, among others. The company was founded in 1999 and is based in Beijing, China.
The domestic production drug registration marketing application for ticagrelor tablets, 60 mg and 90 mg, from Duoduo Pharmaceutical, a subsidiary of Zhongguancun, has been accepted by the National Medical Products Administration. Beijing Zhongguancun Science-Technology Development Holding Company announced on September 10, 2026, that Duoduo Pharmaceutical had received the acceptance notice issued by the National Medical Products Administration, with the registration classified as chemical drug category 4. Ticagrelor tablets are indicated for use with aspirin to reduce the incidence of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events. The original drug was developed by AstraZeneca AB, approved for marketing in the European Union in December 2010, approved by the U.S. FDA in July 2011, and the original product was approved in China in 2012 and 2017 respectively. As of August 31, 2026, cumulative research and development investment in this project was 4.9738 million yuan. The company stated that acceptance of the marketing application marks the entry of this product into the review stage, and if approved smoothly it will enhance market competitiveness and have a positive impact on operating performance.
Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Zhongguancun, has received a Drug Clinical Trial Approval Notice for methylphenidate hydrochloride extended-release chewable tablets, 40 milligram strength, issued by the National Medical Products Administration, approving clinical trials for attention deficit hyperactivity disorder, or ADHD. The drug is intended for treating ADHD patients aged six and older. Currently, only one original imported product is approved for marketing in China, and Beijing Huasu is the first domestic company to obtain clinical trial approval for a generic version of this drug. As of the announcement date, cumulative research and development investment in this project was approximately 5.88 million yuan. The company stated that this approval marks the product's entry into the clinical trial stage, but it still needs to complete clinical trials and pass review and approval before production and marketing. The development cycle is long, involves many steps, and carries uncertainty.
Zhongguancun reports net loss of 29.8 million yuan in 2026 interim results
Zhongguancun released its 2026 interim report, with net profit attributable to the parent company at negative 29.8 million yuan, swinging from profit to loss. Total operating revenue was 1.007 billion yuan, down 18.68 percent from the same period last year. Net cash inflow from operating activities was 122 million yuan, the asset-liability ratio was 53.35 percent, gross margin was 47.61 percent, return on equity was negative 1.87 percent, and diluted earnings per share was negative 0.04 yuan.
Zhongguancun subsidiary Duoduo Pharmaceutical's tramadol hydrochloride injection selected in the 12th batch of national drug centralized procurement
Beijing Zhongguancun Science-Technology Development Holding announced that its subsidiary Duoduo Pharmaceutical's tramadol hydrochloride injection, specification 2ml:100mg, was selected in the 12th batch of national organized drug centralized procurement, becoming one of five selected companies. The procurement cycle runs from the implementation date of the selection results until December 31, 2029, and medical institutions will prioritize selected products and ensure completion of agreed procurement volumes. The product is used to treat moderate to severe pain and is a Class B product under national medical insurance. Its sales revenue in 2025 was approximately 30.44 million yuan, accounting for 1.62% of the company's biomedical business revenue in 2025. The company stated that this selection will help increase product sales volume and market share, and enhance brand influence, while also noting that the signing of procurement contracts and subsequent market sales execution remain uncertain.
The marketing authorization application for Ivabradine Hydrochloride Tablets from Duoduo Pharmaceutical Co., Ltd., a subsidiary of Beijing Zhongguancun Science and Technology Development Holding Co., Ltd., has been accepted by the National Medical Products Administration. The product specification is 5 mg, registered as a Category 4 chemical drug, with acceptance number CYHS2601695. It is indicated for patients with chronic heart failure classified as NYHA class II to IV, with sinus rhythm and a heart rate of 75 beats per minute or higher, accompanied by systolic dysfunction. As of the announcement date, the project has accumulated research and development expenses of 3.6428 million yuan. The company stated that if approved successfully, it will enhance market competitiveness and have a positive impact on business performance, but drug sales are subject to industry policies, market conditions, and other factors, entailing significant uncertainty.
Four Products from Zhongguancun Subsidiary Newly Included in National Essential Medicines List
Zhongguancun announced that a total of 14 products from its subsidiaries have been included in the National Essential Medicines List (2026 Edition), of which four products covering five specifications are newly added, while one product covering one specification has been removed.
Zhongguancun announced that the marketing authorization application for trazodone hydrochloride extended-release tablets from its subsidiary Beijing Huasu Pharmaceutical has been accepted. The drug is used to treat depression with or without anxiety symptoms. As of the announcement date, the project has accumulated research and development expenses of 5.35 million yuan. In the first quarter of 2026, Zhongguancun achieved revenue of 472 million yuan, with a net loss attributable to the parent company of 16.25 million yuan.
Zhongguancun expects net loss attributable to parent of 25 million to 30 million yuan in first half of 2026
Zhongguancun disclosed an earnings forecast, expecting a net loss attributable to the parent of 25 million to 30 million yuan in the first half of 2026, compared with a profit of 38.8089 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 28 million to 33 million yuan, compared with a profit of 36.8549 million yuan in the same period last year. The company stated that the change in performance was mainly due to its core product, benidipine hydrochloride tablets, entering the implementation phase of the eleventh batch of national centralized drug procurement. Affected by the centralized procurement policy, the unit selling price of this product dropped significantly and sales volume declined, causing a substantial impact on operating revenue and operating profit. To cope with the impact, the company is focusing on deepening non-centralized procurement channels, promoting the retail growth of prescription drugs. Strategic products such as oxycodone injection and compound pancreatin powder are rapidly increasing in volume, while the over-the-counter business has achieved notable results in the layout of new retail omni-channels.
China